help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on April 24, 2008
Molecular Endocrinology, doi:10.1210/me.2007-0527
Molecular Endocrinology Vol. 0, No. 2008 200705271-
doi:10.1210/me.2007-0527
Copyright © 2008 by the Endocrine Society.
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
22/7/1622    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Y.-D.
Right arrow Articles by Huang, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Y.-D.
Right arrow Articles by Huang, W.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Nucleotide
*Protein*UniGene
*Compound via MeSH
*Substance via MeSH

Submitted on November 26, 2007
Accepted on April 15, 2008

Farnesoid X Receptor (FXR) Protects Liver Cells from Apoptosis Induced by Serum Deprivation in Vitro and Fasting in Vivo

Yan-Dong Wang, Fan Yang, Wei-Dong Chen, Xiongfei Huang, Lily Lai, Barry M. Forman, and Wendong Huang*

Department of Gene Regulation and Drug Discovery, Beckman Research Institute of City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010

* To whom correspondence should be addressed. E-mail: whuang{at}coh.org.

The farnesoid X receptor (FXR) is a key metabolic regulator in the liver by maintaining the homeostasis of liver metabolites. Recent findings suggest that FXR may have a much broader function in liver physiology and pathology. In the present work, we identify a novel role of FXR in protecting liver cell from apoptosis induced by nutritional withdrawal including serum deprivation in vitro or starvation in vivo. Two FXR ligands, chenodeoxycholic acid (CDCA) and GW4064, rescued HepG2 cells from serum deprivation-induced apoptosis in a dose-dependent manner. This effect of FXR on apoptotic suppression was compromised when FXR was knocked down by siRNA. Similarly, the effects of both CDCA and GW4064 were abolished after inhibition of the MAPK pathway by a specific inhibitor of MEK1/2. Immunoblotting results indicated that FXR activation by CDCA and GW4064 induced ERK1/2 phosphorylation, which was attenuated by serum deprivation. In vivo, FXR-/- mice exhibited an exacerbated liver apoptosis and lower levels of phosphorylated-ERK1/2 compared to wild-type mice after starvation. In conclusion, our results suggest a novel role of FXR in modulating liver cell apoptosis.


Key words: FXR • HepG2 • nutritional withdrawal • apoptosis • ERK1/2

NURSA Molecule Pages Link:

Nuclear Receptors:   FXRα
Ligands:   GW4064






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society